Jiang Tao, Jiang Hui, Su Xiao-Ming, Zheng Lei, Li Quan-Lin, Zhang Zhi-Wei, Li Xian-Cheng
Department of Urology, The First Hospital Affiliated to Dalian Medical University, Dalian, Liaoning 116011, China.
Zhonghua Nan Ke Xue. 2012 Jun;18(6):499-503.
To investigate the expressions of E-cadherin (E-cd) and alpha-catenin (alpha-cat) proteins in benign and malignant prostate tumors, and determine whether they could be used as molecular markers for the prognosis of prostate cancer (PCa).
We detected the expressions of E-cd and alpha-cat in the prostatic tissues from 45 cases of PCa and 10 cases of benign prostatic hyperplasia (BPH) by immunohistochemical Elivision staining, and analyzed the relationships of E-cd and alpha-cat expressions with the PCa stage, PCa grade, preoperative PSA, results of endocrine therapy and prognosis.
The E-cd protein was abnormally expressed in 86.7% of the PCa and 10.0% of the PSA patients, and the E-cd expression was significantly lower in the former than in the latter (P < 0.05). The abnormal expressions of E-cd in the PCa patients with metastasis, non-metastasis, Gleason score < or = 7 and > 7 were 85.0, 87.5, 100.0 and 86.7%, respectively, with no significant between-group differences (P > 0.05), those in the PCa patients with PSA < or = 10 and > 10 microg/L were 40.0 and 97.1%, respectively, significantly higher in the former than in the latter (P < 0.05), and those in the PCa patients with and without response to endocrine therapy were 93.8 and 72.7%, respectively, with no significant differences between the two groups (P > 0.05). The alpha-cat protein was abnormally expressed in 93.3% of the PCa and 30.0% of the BPH patients, respectively, and the alpha-cat expression was significantly lower in the former than in the latter (P < 0.05). The abnormal alpha-cat expressions in the PCa patients with metastasis, non-metastasis, Gleason score > 7 and < or = 7 were 90.0, 100.0, 90.0 and 100.0%, respectively, with no significant between-group differences (P > 0.05), those in the PCa patients with PSA < or = 10 and > 10 microg/L were 40.0 and 94.3%, respectively, significantly higher in the former than in the latter (P < 0.05), and those in the PCa patients with and without response to endocrine therapy were 100.0 and 81.8%, respectively, with no significant differences between the two groups (P > 0.05).
The expressions of E-cd and alpha-cat are significantly lower in PCa than in BPH, and they are not associated with cancerous metastasis, but negatively correlated with the PSA level in PCa patients.
研究E-钙黏蛋白（E-cd）和α-连环蛋白（α-cat）蛋白在前列腺良恶性肿瘤中的表达情况，并确定它们是否可作为前列腺癌（PCa）预后的分子标志物。
采用免疫组化Elivision染色法检测45例PCa患者和10例良性前列腺增生（BPH）患者前列腺组织中E-cd和α-cat的表达，并分析E-cd和α-cat表达与PCa分期、分级、术前前列腺特异抗原（PSA）、内分泌治疗效果及预后的关系。
E-cd蛋白在86.7%的PCa患者和10.0%的BPH患者中异常表达，前者表达明显低于后者（P<0.05）。发生转移、未发生转移、Gleason评分≤7和>7的PCa患者中E-cd异常表达率分别为85.0%、87.5%、100.0%和86.7%，组间差异无统计学意义（P>0.05）；PSA≤10和>10μg/L的PCa患者中E-cd异常表达率分别为40.0%和97.1%，前者明显低于后者（P<0.05）；内分泌治疗有反应和无反应的PCa患者中E-cd异常表达率分别为93.8%和72.7%，两组差异无统计学意义（P>0.05）。α-cat蛋白在93.3%的PCa患者和30.0%的BPH患者中异常表达，前者表达明显低于后者（P<0.05）。发生转移、未发生转移、Gleason评分>7和≤7的PCa患者中α-cat异常表达率分别为90.0%、100.0%、90.0%和100.0%，组间差异无统计学意义（P>0.05）；PSA≤10和>10μg/L的PCa患者中α-cat异常表达率分别为40.0%和94.3%，前者明显低于后者（P<0.05）；内分泌治疗有反应和无反应的PCa患者中α-cat异常表达率分别为100.0%和81.8%，两组差异无统计学意义（P>0.05）。
PCa中E-cd和α-cat的表达明显低于BPH，它们与癌转移无关，但与PCa患者的PSA水平呈负相关。
